West Pharmaceutical Services (NYSE:WST) Sets New 52-Week High – Here’s What Happened

West Pharmaceutical Services, Inc. (NYSE:WST) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $333.89 and last traded at $331.6530, with a volume of 31127 shares. The stock had previously closed at $319.75.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 target price on the stock. Morgan Stanley increased their target price on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the stock an “equal weight” rating in a research note on Friday, May 29th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Finally, UBS Group reissued a “buy” rating and set a $340.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, West Pharmaceutical Services currently has an average rating of “Buy” and a consensus price target of $340.09.

West Pharmaceutical Services Price Performance

The stock has a market capitalization of $23.44 billion, a P/E ratio of 44.35, a price-to-earnings-growth ratio of 2.80 and a beta of 1.18. The business’s 50 day simple moving average is $295.87 and its two-hundred day simple moving average is $270.81. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.68 million. During the same period last year, the firm earned $1.45 earnings per share. The business’s quarterly revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

West Pharmaceutical Services declared that its board has authorized a share repurchase plan on Tuesday, February 17th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is currently owned by company insiders.

Institutional Trading of West Pharmaceutical Services

Several institutional investors and hedge funds have recently made changes to their positions in the company. Glenmede Trust Co. NA raised its holdings in shares of West Pharmaceutical Services by 3.0% in the first quarter. Glenmede Trust Co. NA now owns 4,370 shares of the medical instruments supplier’s stock valued at $1,095,000 after purchasing an additional 126 shares during the last quarter. Oddo BHF Asset Management Sas raised its holdings in shares of West Pharmaceutical Services by 4.9% in the first quarter. Oddo BHF Asset Management Sas now owns 4,990 shares of the medical instruments supplier’s stock valued at $1,251,000 after purchasing an additional 235 shares during the last quarter. Amundi raised its holdings in shares of West Pharmaceutical Services by 85.4% in the first quarter. Amundi now owns 644,065 shares of the medical instruments supplier’s stock valued at $161,428,000 after purchasing an additional 296,639 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of West Pharmaceutical Services by 39.0% in the first quarter. Empowered Funds LLC now owns 2,717 shares of the medical instruments supplier’s stock valued at $681,000 after purchasing an additional 762 shares during the last quarter. Finally, Evelyn Partners Investment Management Services Ltd purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at about $54,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.